Quick Answer
Vir Biotechnology, Inc. reported Total Revenue of $68.56 million for fiscal year 2025.
Vir Biotechnology, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $68.56M -7.6% |
$74.20M -13.9% |
$86.18M -94.7% |
$1.62B +47.5% |
$1.10B +1334.4% |
$76.37M +843.9% |
| Net Income | -$437.99M +16.1% |
-$521.96M +15.1% |
-$615.06M -219.2% |
$515.84M -2.4% |
$528.58M +277.0% |
-$298.67M -71.0% |
| Diluted EPS | -$3.16 +17.5% |
-$3.83 +16.6% |
-$4.59 -219.8% |
$3.83 -3.3% |
$3.96 +257.8% |
-$2.51 +56.4% |
| Total Assets | $1.00B -28.3% |
$1.40B -27.1% |
$1.92B -31.5% |
$2.80B +43.4% |
$1.95B +112.7% |
$918.76M +79.4% |
| Cash and Equivalents | $232.19M +4.1% |
$222.95M -7.7% |
$241.58M -71.5% |
$848.63M +144.0% |
$347.81M -20.3% |
$436.57M +299.3% |
| Stockholders Equity | $765.28M -33.5% |
$1.15B -27.7% |
$1.59B -23.5% |
$2.08B +45.1% |
$1.43B +99.7% |
$716.85M +69.1% |
| R&D Expense | $455.97M -10.0% |
$506.50M -12.6% |
$579.72M +22.1% |
$474.65M +5.9% |
$448.01M +48.1% |
$302.41M +103.7% |
| Operating Income | -$479.33M +18.4% |
-$587.16M +14.2% |
-$684.30M -182.1% |
$833.07M +98.0% |
$420.75M +241.7% |
-$296.98M -66.9% |
| Shares Outstanding | 139.47M +1.8% |
136.96M +1.6% |
134.78M +1.2% |
133.24M +1.6% |
131.16M +2.9% |
127.42M +18.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $240.0K | -89.9% | -80.2% |
| Net Income | September 30, 2025 | -$163.14M | +23.7% | -47.0% |
| Diluted EPS | September 30, 2025 | -$1.17 | +25.0% | -46.2% |
| Total Assets | September 30, 2025 | $1.02B | -32.0% | -14.5% |
| Cash and Equivalents | September 30, 2025 | $170.08M | +1.0% | -19.4% |
| Stockholders Equity | September 30, 2025 | $796.10M | -35.8% | -16.0% |
| R&D Expense | September 30, 2025 | $151.46M | -22.4% | +55.3% |
| Operating Income | September 30, 2025 | -$173.44M | +25.0% | -46.5% |
| Shares Outstanding | September 30, 2025 | 139.02M | +1.7% | +0.1% |
- Vir Biotechnology, Inc. reported Total Revenue of $68.56 million for fiscal year 2025.
- Vir Biotechnology, Inc. showed a decrease of -7.6% in Total Revenue compared to the prior fiscal year.
- Vir Biotechnology, Inc. reported Net Income of -$437.99 million for fiscal year 2025.
- Vir Biotechnology, Inc. showed an increase of +16.1% in Net Income compared to the prior fiscal year.
- Vir Biotechnology, Inc. reported Diluted EPS of $3.16 per share (loss) for fiscal year 2025.
- Vir Biotechnology, Inc. showed an increase of +17.5% in Diluted EPS compared to the prior fiscal year.
- Vir Biotechnology, Inc. reported Total Assets of $1.00 billion for fiscal year 2025.
- Vir Biotechnology, Inc. showed a decrease of -28.3% in Total Assets compared to the prior fiscal year.
- Vir Biotechnology, Inc. reported Cash and Equivalents of $232.19 million for fiscal year 2025.
- Vir Biotechnology, Inc. showed an increase of +4.1% in Cash and Equivalents compared to the prior fiscal year.
- Vir Biotechnology, Inc. reported Stockholders Equity of $765.28 million for fiscal year 2025.
- Vir Biotechnology, Inc. showed a decrease of -33.5% in Stockholders Equity compared to the prior fiscal year.
- Vir Biotechnology, Inc. reported R&D Expense of $455.97 million for fiscal year 2025.
- Vir Biotechnology, Inc. showed a decrease of -10.0% in R&D Expense compared to the prior fiscal year.
- Vir Biotechnology, Inc. reported Operating Income of -$479.33 million for fiscal year 2025.
- Vir Biotechnology, Inc. showed an increase of +18.4% in Operating Income compared to the prior fiscal year.
- Vir Biotechnology, Inc. reported Shares Outstanding of 139.47 million shares for fiscal year 2025.
- Vir Biotechnology, Inc. showed an increase of +1.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: